MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment
MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced translational data supporting the favourable immunological effects of MTL-CEBPA and its benefits in combination with other cancer therapies including anti-PD1 checkpoint inhibition. The studies combine pre-clinical research conducted at the Wistar Institute as well as biomarker analysis of the previously completed OUTREACH clinical trial. MTL-CEBPA is the first candidate from MiNA s pipeline of small activating RNA therapeutics, a new class of medicines to restore normal cell function. The data will be presented during a poster session at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually from April 10 April 15, 2021.
CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting
- First study evaluating CAR-macrophages in fully immunocompetent solid tumor mouse models shows significant tumor control, increased survival, and induction of anti-tumor immunity
- New ultra-rapid, same-day CAR-monocyte manufacturing process may reduce vein-to-vein time
News provided by
Share this article
Share this article
PHILADELPHIA, April 9, 2021 /PRNewswire/ CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for virtual presentation at The American Association for Cancer Research (AACR) Annual Meeting on Saturday, April 10 – Thursday, April 15. The accepted data reinforces the potential of CARISMA s proprietary chimeric antigen receptor macrophage (CAR-M) platform, as well as the importance of evaluating CAR-monocytes (CAR-Mono) as a novel and exped
Session Time: April 13, 11:17-11:39 a.m. EST
Summary: Kaelin will highlight the important physiologic constraints a cancer tissue must operate within, focusing on the critical role hypoxia plays in not only tumor growth but progression, and how modulating the hypoxia machinery will limit tumor progression. The ability to target cancer at several molecular levels provides hope that our therapies will not only be more effective but also more durable. The lingering question is how to deploy these approaches by identifying which patients are most likely to benefit.
In addition to the exciting research presentations, Andrew Aguirre, MD, PhD, of the Dana-Farber Center for Gastrointestinal Oncology, has been named a 2021 AACR NextGen Star. Aguirre will present during the NextGen Stars Spotlight Session: Genetics and Epigenetics.